Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplify Transformational Data Sharing ETF (BLOK) vs Heron Therapeutics Inc (HRTX) Price & Performance

Amplify Transformational Data Sharing ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Amplify Transformational Data Sharing ETF vs Heron Therapeutics Inc — how do they compare? Amplify Transformational Data Sharing ETF trades at $61.25, while Heron Therapeutics Inc trades at $0.42 (market cap $82.52M). The key difference: Amplify Transformational Data Sharing ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

BLOKHRTX
52-Week High
$74.10$2.04
52-Week Low
$47.36$0.39
Market Cap
$82.52M
Sector
Health
Enterprise Value
$180.42M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplify Transformational Data Sharing ETF

BLOK trades at $60.81, down 2.95% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights the fund's diversified blockchain economy exposure, including bitcoin miners and enterprise adopters. The company announced a $0.08 dividend scheduled for June 2026, providing income potential for shareholders.

Outlook remains cautious with technical indicators signaling bearish momentum. The fund's increased bitcoin exposure to approximately 40% introduces volatility risks, though diversification across AI infrastructure and payment processors offers some stability. Investment opportunity exists for long-term investors seeking blockchain economy exposure, but near-term performance depends heavily on crypto market direction and AI infrastructure growth.

Heron Therapeutics Inc

HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.

While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.

Returns comparison

Trailing returns across standard periods

About Amplify Transformational Data Sharing ETF

The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.

Read more on BLOK

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX